WATS3D for Esophageal Conditions: A 5-Year Study
This study is creating a registry (a research database) to learn more about two ways of taking tissue samples from your esophagus (the tube that carries food to your stomach). These methods are using forceps and using a brush to collect small tissue samples. The study will look at how the brush biopsy results affect your doctor's decisions about your future care. Researchers also want to see if either the brush biopsy, the forceps biopsy, or both can predict who with heartburn might develop Barrett's esophagus (a condition that can lead to cancer) or who with Barrett's esophagus might develop precancer or cancer. You can join if you are 18 or older, having an upper endoscopy with both types of biopsies as part of your standard care, and can understand and sign the consent form. The study will follow participants for 5 years.
- Study design
- This is an observational study, meaning researchers will collect data without giving you a specific treatment. It plans to include 90,000 participants.
- What's involved
- You will undergo an upper endoscopy with forceps and brush biopsies as part of your standard medical care. Your biopsy results will be recorded over 5 years.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your biopsy results will be recorded over 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Clinical Utility of WATS3D: A 5-Year Prospective Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Matthew McKinley, M.D. · PRINCIPAL_INVESTIGATOR · NYU Langone Health
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Primary Outcome Measure:5 years
Clinical Utility of WATS3D as determined by how many patients undergo increased surveillance, radiofrequency ablation and placement on PPIs.